Mutations in the presenilin-1 (PSEN1) gene are associated with familial Alzheimer's disease and frontotemporal dementia (FTD). Interestingly, neuropathological analysis of a Belgian FTD family carrying a PSEN1 c.548G>T mutation confirmed neurodegeneration in the absence of amyloid plaques. To investigate the impact of the c.548G>T mutation on presenilin-1 (PS1) function in vivo, we introduced this mutation into the genomic Psen1 locus. The resulting c.548G>T knock-in (KI) mice are viable but express markedly lower levels of Psen1 mRNA and protein in the brain. This reduction is due to production of aberrantly spliced transcripts lacking either exon 6 or exons 6 and 7 and their subsequent degradation via non-sense-mediated decay (NMD); inhibition of NMD by cycloheximide treatment stabilized these transcripts and restored the level of Psen1 mRNA in KI/KI brains. Interestingly, the reduction of Psen1 mRNA expression and the degradation of aberrant Psen1 splice products occur exclusively in the brain but not in other tissues. Consistent with decreased Psen1 expression, ␥-secretase activity was strongly reduced in the cerebral cortex of KI mice, as measured by de novo ␥-secretase-mediated cleavage of APP and Notch. Moreover, PS1 expressed from Psen1 cDNA carrying the c.548G>T mutation displayed normal ␥-secretase activity in cultured cells, indicating that the corresponding p.183GϾV amino acid substitution does not affect ␥-secretase activity. Finally, Psen1 c.548G>T KI/KI ;Psen2 Ϫ/Ϫ mice exhibited mild spatial memory deficits in the Morris water maze task. Together, our findings demonstrate that the c.548G>T mutation results in a brain-specific loss of presenilin function due to decreased Psen1 mRNA expression.
Introduction
Frontotemporal dementia (FTD) is the second most common form of dementia following Alzheimer's disease (AD) (Sjögren and Andersen, 2006) . FTD is a clinically diverse syndrome characterized by profound behavioral changes and degeneration of the frontal and anterior temporal cortex (Neary et al., 2005) . Due to the clinical and neuropathological heterogeneity, FTD comprises a number of related disorders with overlapping but distinct features, including Pick's disease and frontotemporal lobar degeneration. For example, tau pathology is present in some FTD cases, whereas others lack tau deposition. A large proportion (ϳ20 -50%) of FTD cases have a familial component, and mutations in microtubule-associated protein tau and progranulin genes are the most frequent genetic causes (Galimberti and Scarpini, 2010) . Interestingly, mutations in the presenilin-1 (PSEN1) and PSEN2 genes, which are the major cause of familial AD, have also been implicated in FTD (Mendez and McMurtray, 2006) . Since the first identification of the PSEN1 c.338TϾC mutation in cases of familial dementia with prominent clinical frontotemporal features (Raux et al., 2000) , Ͼ10 mutations in the PSEN genes have been associated with clinical diagnoses of FTD, in some cases accompanied by frontotemporal atrophy and frontotemporal hypoperfusion on neuroimaging studies (Rippon et al., 2003; Dermaut et al., 2004; Halliday et al., 2005; Zekanowski et al., 2006; Bernardi et al., 2009; de Bot et al., 2009; Marcon et al., 2009; Gallo et al., 2010; Borroni et al., 2011) . Moreover, some pathogenic PSEN1 mutations can cause neuropathological changes consistent with coexisting Pick's disease and AD (Ikeda et al., 1996; Halliday et al., 2005) . Interestingly, several of these mutations reside at the exon/intron boundaries and, therefore, may affect PSEN1 splicing in addition to causing mis-sense substitutions (Raux et al., 2000; Dermaut et al., 2004; Borroni et al., 2011) . Thus, mutations in PSEN may result in overlapping clinical and neuropathological manifestations of AD and FTD, and functional changes of presenilin (PS) may underlie common pathogenesis of both dementias.
To investigate how PSEN mutations may be associated with FTD, we chose the PSEN1 c.548GϾT mutation, which was originally identified in familial FTD patients with neuropathological confirmation of Pick's-type tauopathy in the absence of amyloid deposition (Dermaut et al., 2004) . Since the c.548GϾT mutation resides at the last nucleotide of exon 6, we generated knock-in (KI) mice in which the c.548GϾT mutation was introduced into the genomic Psen1 locus. The c.548GϾT
KI/KI mice are viable, but Psen1 mRNAs are significantly decreased selectively in the brain due to aberrant exon skipping and subsequent degradation of aberrantly spliced transcripts by non-sensemediated mRNA decay. Accordingly, ␥-secretase activity is reduced in the KI brain, as measured by ␥-secretasemediated cleavage of two physiological substrates, Notch and amyloid precursor protein (APP). However, PS1 expressed from full-length Psen1 c.548GϾT mRNA displayed normal ␥-secretase activity when tested in cultured cells. Furthermore,
Psen1
KI/KI ;Psen2 Ϫ/Ϫ mice exhibited a significant deficit in spatial reference memory. Together, these findings demonstrate that the c.548GϾT mutation causes brain-specific reduction of Psen1 mRNA expression and PS function in the maintenance of ␥-secretase activity and memory.
Materials and Methods
Generation of Psen1 c.548GϾT KI mice. For the Psen1 c.548GϾT KI construct, a 2.49 kb leftarm fragment and a 3.15 kb right-arm fragment surrounding exon 6 were amplified by PCR using BAC (bacterial artificial chromosome) DNA harboring the mouse Psen1 gene (clone RP23-330F11, Children's Hospital Oakland Research Institute) as a template. The primer sequences are 5Ј-TACCGCGG AATGGGATGTGTGTGTTGGGATGC-3Ј and 5Ј-TGGCGGCCGCATGTGAGAATCCTGGG TGCAGTC-3Ј for the left-arm (the italic sequences are for SacII and NotI, respectively), and 5Ј-GCGTCGACAAGTATGTGCTGATC CCCAAAGC-3Ј and 5Ј-GCAAGCTTAAGT GCTGGGATTACAGGAGGAC-3Ј for the rightarm (the italic sequences are for SalI and HindIII recognition sites, respectively). The c.548GϾT pathogenic mutation (encoding a mis-sense mutation, p.183GϾV) and c.546AϾG humanized nucleotide change (a silent mutation for Leu at the amino acid residue 182) were introduced by site-directed mutagenesis into exon 6 in the right-arm fragment (see Fig. 1 A) (only c.548GϾT mutation will be described hereafter). The left-and right-arm fragments were then subcloned into the SacII-NotI site and the SalI-HindIII site of the PGKneolox2DTA plasmid (gift of P. Soriano, Mount Sinai School of Medicine, New York, NY), respectively, to produce the KI targeting vector (Fig. 1B) , which was then confirmed by extensive restriction digestions and sequencing. The linearized targeting Figure 1 . Generation of Psen1 c.548GϾT KI mice. A, Sequence alignment at the boundary of PSEN1 exon 6 and intron 6, where the c.548GϾT mutation resides, among human wild-type and FTD (c.548GϾT ) as well as mouse KI (c.548GϾT ) alleles. The nucleotides and amino acid residues in red indicate the c.548GϾT mutation and the subsequent p.183GϾV alteration in FTD patients and KI mice. B, Targeting strategy for the generation of c.548GϾT KI mice. The green boxes represent Psen1 exons 5-9. The c.548GϾT mutation is located at the last nucleotide of exon 6. Ba, BamHI. C, Southern analysis of tail genomic DNAs from mice carrying either the targeted allele (after homologous recombination but before Cre-mediated site-specific recombination to remove the floxed PGK-neo cassette) or the KI allele (after the removal of the floxed PGK-neo cassette) using the 5Ј or 3Ј external probe. Tail genomic DNAs were digested with BamHI. The 11.0 kb recognized by either the 5Ј or the 3Ј external probe represents the wild-type allele, whereas the 5.5 kb fragment recognized by the 5Ј external probe represents the targeted or the KI allele. The 3Ј external probe gives rise to 8.5 and 6.2 kb fragments, which represent the targeted and KI alleles, respectively. D, Sequencing of PCR products from c.548GϾT KI/KI genomic tail DNAs confirms the correct introduction of the c.548GϾT KI mutation. E, Nissl staining of sagittal brain sections of c.548GϾT
KI/KI and littermate wild-type mice shows similar brain morphology. Stereological assessment of cortical volume using a series of 10 m sagittal sections from KI/KI and wild-type (ϩ/ϩ) littermate mice at ϳ2 years of age (n ϭ 4 per genotype) reveals similar cortical volume between the two genotypic groups. The representative comparable sections are shown. F, Western analysis shows similar GFAP signals in the brain of KI/KI and control mice at 12-20 months of age. NS, Not significant.
vector by XhoI was electroporated into MKV6.5 ES cells (gift of R. Jaenisch, Whitehead Institute, Cambridge, MA) and selected with 150 g/ml G418 (Invitrogen) for 4 -5 d. Genomic DNAs were purified from a total of 360 independent ES clones and were subjected to Southern analysis using the 5Ј probe. For Southern analysis, genomic DNAs were digested with BamHI. Among 52 clones that tested positive for proper homologous recombination in the 5Ј arm, 3 ES clones (3-9-H, 4 -1-F, 7-11-A) were expanded and subjected to further Southern analysis using the 5Ј, 3Ј, and neomycin probes (Fig. 1 B) . We confirmed that homologous recombination correctly occurred in both the 5Ј and 3Ј homologous regions in these three clones. To generate Psen1 c.548GϾT KI mice, the targeted ES cells (clones 4 -1-F and 7-11-A) were injected into C57BL/6 blastocysts, and the resulting male chimeric mice were mated with C57BL/6J-129 F1 mice. Mice transmitting the targeted allele were further crossed to ␣CaMKII-Cre male transgenic mice (Yu et al., 2001) to excise the floxed phosphoglycerate-kinase-neomycin (PGKneo) cassette, as the ␣CaMKII promoter allows the Cre transgene to express weakly in male germ cells (Ignotz and Suarez, 2005) . The resulting progeny (KI heterozygous mice) were intercrossed to obtain homozygous KI mice for further characterization. Correct homologous and Cre-mediated sitespecific recombination events were further confirmed by Southern analysis with tail genomic DNAs using the external 5Ј, 3Ј, and neo probes, and by sequencing to detect the presence of the c.548GϾT mutation in genomic DNAs. Since offspring from both targeted ES clones 4 -1-F and 7-11-A were indistinguishable, we used the KI mice derived from the ES clone 4 -1-F for further characterization. In subsequent generations, mice were genotyped routinely by PCR, and the c.548GϾT KI allele was detected by size shift due to the remaining loxP and construct sequence between exons 5 and 6 using the following primers: 5Ј-TGGTGAGAGCTCAGCAGGTAAG-3Ј and 5Ј-TGCTTTCTAGTTGTCCTTCGTCG-3Ј. The 410 bp band represents the wild-type allele, whereas the 529 bp band represents the KI allele. Psen1 c.548GϾT
KI/KI ;Psen2 Ϫ/Ϫ mice were generated by breeding Psen1 c.548GϾT KI mice with Psen2 Ϫ/Ϫ mice, which exhibited no detectable phenotypes (Steiner et al., 1999) . The genetic background of all the mice used in this study was C57BL/6J 129 F1 hybrid. All procedures relating to animal care and treatment conformed to the institutional and NIH guidelines.
qRT-PCR and Northern analyses. Total RNAs were purified with TRI reagent (Sigma) according to manufacturer's protocol, treated with DNase I, and reverse transcribed in the presence of random hexamers and SuperScript III Reverse Transcriptase (Invitrogen). PCRs were performed using SYBR Green PCR Master Mix with a 7500 Fast Real-Time PCR System (Applied Biosystems) using cDNA and gene-specific primers. Reactions were performed in triplicate, and threshold cycle values were normalized to those of Gapdh. The primer pairs used in this study were as follows: 5Ј-TGGCCACCATCAAATCAG-3Ј and 5Ј-TC ATGATGGCCGCATTCAG-3Ј for Psen1; and 5Ј-TTGTCTCCTGCGACTTCA-3Ј and 5Ј-TCCACCACCCTGTTGCTGTA-3Ј for Gapdh. These primer pairs were confirmed not to give rise to primer dimers during the PCR. For Northern analysis, 10 -20 g of total RNA was separated in formaldehyde agarose gels and transferred to nylon membranes (GE Healthcare). Hybridization was performed using [␣-32 P] dCTP-labeled probes specific for each gene. Almost the entire coding region of the mouse Psen1 gene was used for a Psen1-specific probe so as to detect any possible transcriptional/posttranscriptional variant from the Psen1 gene. Western analysis. Dissected cortices (at 1-2 months for c.548GϾT KI mice) were homogenized in RIPA buffer [50 mM Tris-Cl, pH 7.6, 150 mM NaCl, 0.5 mM EDTA, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, protease inhibitor cocktail (Sigma), 1 mM PMSF]. Equal amounts (10 -40 g per lane) of proteins were separated in NuPAGE gels (Invitrogen) and transferred to nitrocellulose membranes. The membranes were blocked in 5% nonfat milk/TBS for 1 h and incubated with specific primary antibodies as follows: rabbit anti-PS1 N-terminal fragments (NTFs; catalog #529591, Calbiochem); rabbit anti-PS1 C-terminal fragments (CTFs; catalog #529592, Calbiochem); rabbit anti-Pen2 (catalog #36 -7100, Zymed); rabbit anti-nicastrin (NCT; N1660, Sigma); rabbit anti-Aph1 (PA1-2010, Thermo science); mouse anti-␣-tubulin (T6199, Sigma); mouse anti-phospho-tau (PHF1 and CP13, gift of P. Davies, Albert Einstein College of Medicine, New York, NY); rabbit anti-total tau (JM, gift of A. Takashima, RIKEN, Saitama, Japan); rabbit anti-Notch1 (V1744) (catalog #2421, Cell Signal Tech); and mouse anti-SNAP25 (MAB331, Millipore Bioscience Research Reagents). The membrane was then incubated with IRDye 800CW or IRDye 680-labeled secondary antibodies (LI-COR Bioscience). Signals were developed and quantified with an Odyssey Infrared Imaging System (LI-COR Bioscience).
Administration of cycloheximide. Drug administration was performed as described previously (Contet et al., 2007) . Briefly, cycloheximide (Sigma) or saline was intraperitoneally administered at 1 h intervals (200 KI/KI brains at all ages examined, and the reduction appears most dramatic at postnatal day 1. B, qRT-PCR analysis of Psen1 mRNAs in the cortices of KI/KI, KI/ϩ, and littermate controls at 2 months of age. The levels of Psen1 mRNAs are decreased depending on the KI allele dosage (n Ն 4 per genotype), with ϳ40% reduction in KI/KI. C, Effects of the c.548GϾT mutation on levels of ␥-secretase complex proteins. Western analysis shows ϳ30% decreases of PS1 NTFs and CTFs in c.548GϾT KI/KI brains at 2 months of age (n Ն 4 per genotype). In contrast, other components (nicastrin, Aph-1, and Pen-2) are present at comparable levels between the genotypic groups. *p Ͻ 0.05; **p Ͻ 0.01. NS, Not significant. All data are expressed as mean Ϯ SEM. mg/kg body weight). Tissues were dissected and frozen for further molecular analysis 4 h after the first injection.
Cell-based ␥-secretase assay. Psen-deficient mouse embryonic fibroblasts (MEFs) were transfected with equal amounts (1 ng) of expression vectors encoding wild-type or various mutant PS1 along with an N-terminally truncated Notch1 construct (N⌬E, gift of A. Goate, Washington University School of Medicine, St. Louis, MO) as described previously (Heilig et al., 2010) . The amount of plasmid DNA used was derived from a dose-curve analysis using 0.125, 0.25, 0.5, 1.0, 2.0, 4.0, and 8.0 ng of Psen1 wild-type cDNAs, and doses within the linear range were 0.5 (0.5ϫ), 1.0 (1ϫ) and 2.0 (2ϫ) ng. A 1.7 kb mouse Psen1 coding sequence was amplified with primers 5Ј-GATCTCGAGTTC GAGGTCTTTAGGCAGCTTG-3Ј and 5Ј-AG TGCGGCCGCTGCTGCAGCGATGGATGTT GG-3Ј (italics indicates XhoI and NotI sequences, respectively), and subcloned into XhoI-NotI sites of pCI expression vector (Invitrogen). The corresponding mutations of each mutant PS1 were introduced by either subcloning or site-directed mutagenesis. Cells were harvested with RIPA buffer 24 h after transfection, and Western analysis was performed using anti-Notch1 (V1744) antibody (catalog #2421, Cell Signal Tech). Data are normalized to ␣-tubulin, and three independent experiments were quantified.
In vitro ␥-secretase assay. ␥-Secretasemediated de novo amyloid-␤ (A␤) generation was measured using a method described previously (Takahashi et al., 2003) . Briefly, the cortices at 1-2 months of age were homogenized in homogenization buffer (20 mM PIPES, pH 7.0, 140 mM KCl, 0.25 M sucrose, 5 mM EGTA) using a glass/Teflon tissue grinder. The homogenates were centrifuged at 800 ϫ g for 10 min to remove nuclei and cell debris. The postnuclear supernatants were recentrifuged at 100,000 ϫ g for 1 h, and the resulting pellets were washed with 0.1 M sodium carbonate, pH 11.4, and then centrifuged again. The membrane pellets were solubilized with 1% 3-[(3-cholamidopropyl) dimethylammonio]-2-hydroxy-1-propanesulfonate (CHAPSO) in homogenization buffer for 1 h on ice and then centrifuged at 100,000 ϫ g for 1 h, and finally the resulting soluble fractions were saved at Ϫ80°C until used as crude ␥-secretase fractions. For in vitro ␥-secretase assay, the CHAPSO-soluble microsomal proteins were mixed with assay buffer [10 mM HEPES, pH 7.3, 150 mM NaCl, 1 mM EDTA, complete protease inhibitor cocktail (Roche), 5 mM 1,10-phenanthroline, 5 mg/ml phosphoramidon, and 0.1% (w/v) phosphatidylcholine], and incubated with recombinant C100-FmH or N102-FmH (1-2 M) as a ␥-secretase substrate at 37°C for 14 h. To quantify de novo A␤ generation, samples were subjected to ELISA specific for A␤40 and A␤42. Specific ␥-secretase activity was obtained by subtracting the values obtained from a reaction conducted in the presence of ␥-secretase inhibitor (III-31C, Sigma). For Western analysis of in vitro ␥-secretase assay, specific signals of cleaved substrate were normalized by the signals of SNAP25. For recombinant C100-FmH and N102-FmH, which are tagged with Flag-Myc-Histidine, bacterial strain DH5␣ was transformed with pTrcHis2A-C100-FmH and pTrcHis2A-N102-FmH plasmids (gifts of T. Iwatsubo and T. Tomita, University of Tokyo, Tokyo, Japan), respectively, and induced with 0.1 mM Isopropyl ␤-D-1-thiogalactopyranoside for 3 h. Each recombinant protein was purified with Ni 2ϩ -chelated HiTrap Chelating HP column (GE Healthcare).
ELISA. Monoclonal antibodies directed against the C terminus of A␤40 (11A50-B10, Covance) or A␤42 (12F4, Covance) were used for specific capture of A␤ species. A biotinylated monoclonal secondary antibody (4G8, Covance) recognizing A␤ residues 17-24 was used for detection of both A␤x-40 and A␤x-42 with a reporter system of streptavidin-conjugated alkaline phosphatase (Promega) and AttoPhos reagent (Promega). Fluorescence was measured with excitation at 444 nm and emission at 555 nm by a Synergy HT microplate reader (BioTek). A␤40 and A␤42 synthetic peptide standards (BioPeptide) were included in each analysis for quantifying A␤ levels, which were expressed as the picomolar concentration of A␤x-40 or A␤x-42. For endogenous mouse A␤ ELISA, mouse cortices were homogenized in 0.2% diethylamine and centrifuged at 100,000 ϫ g. The resulting supernatants were neutralized with Tris-Cl, pH 6.8, and directly used for A␤ measurement. Monoclonal antibodies were used for capture of A␤40 (266) and A␤42 (21F12), and biotinylated mono- KI/KI brains. RT-PCR using primers in exons 4 and 10 reveals low levels of two aberrant Psen1 splice products (716 bp, 495 bp) in c.548GϾT
KI/KI brains in addition to correctly spliced mRNAs (784 bp). Sequencing analysis of these two aberrant splice products revealed absence of either exon 6 or both exons 6 (68 bp) and 7 (221 bp). Right, The structure of full-length Psen1 mRNAs and aberrantly spliced products; the green areas represent coding sequences. The skipping of exon 6 or both exons 6 and 7 results in frame-shift and out-of-frame stop codons becoming in frame in exons 7 or 9, respectively. B, RT-PCR analysis shows that administration of cycloheximide, which inhibits protein synthesis and non-sense-mediated mRNA decay, increased levels of the aberrantly spliced products in KI/KI brains, indicating that the reduction of Psen1 mRNAs in KI/KI brains is due to degradation of aberrantly spliced transcripts by non-sensemediated mRNA decay. C, qRT-PCR using cortical total RNAs of KI/KI mice injected with cycloheximide or saline reveals that administration of cycloheximide reverses the reduction of full-length Psen1 mRNAs in KI/KI brains (n ϭ 3). *p Ͻ 0.05. All data are expressed as mean Ϯ SEM.
clonal secondary antibodies were used for detection of A␤40 (2G3) and A␤42 (266). Endogenous A␤ concentration was calculated to divide the total A␤ amount by the total protein amount in the cortex fraction.
Behavioral analysis. The Morris water maze is a circular pool 160 cm in diameter. Mice were housed in a standard 12 h light/dark cycle. Before testing, the experimenter handles each mouse for 5 min/d for 5 d. During the hidden platform training, the platform (10 cm in diameter) was kept submerged under water and maintained in the same position. Each mouse was given four trials daily with a maximum duration of 90 s separated by a minimum of 15 min. If the mouse did not find the hidden platform, it was guided to the platform and allowed to remain on it for 15 s. The swimming of the mice was monitored using an automated tracking system (HVS Image). A group of mice aged 6 -8 months (Psen1 c.548GϾT
KI/KI ;Psen2 Ϫ/Ϫ and Psen1 ϩ/ϩ ;Psen2 Ϫ/Ϫ ) or 18 -20 months (Psen1 c.548GϾT
KI/KI and Psen1 ϩ/ϩ ) were trained in the hidden platform task for 12 d. Twenty-four hours after the last training (day 12), the hidden platform was removed and a 90 s probe trial was performed to test a spatial reference memory. The mice were released from all four quadrants in a pseudorandom manner during the training and the probe trial. Finally, the visible cue task with four trials was performed to verify visual and swimming ability using the platform marked by a yellow object. The experimenters were blind to the genotypes of the mice.
Histological analysis. Brains were perfused with PBS, fixed in 4% paraformaldehyde for 3 h at 4°C, and processed for paraffin embedding. Paraffin-embedded sagittal sections were serially cut at 10 m. Sections in every 40 slides were deparaffinized, dehydrated, and stained with 0.5% Cresyl Violet (Sigma), and analyzed for brain volumes by BioQuant image analysis software. For immunohistochemistry, paraffin-embedded brain sections were deparaffinized, alcohol dehydrated, and immunostained with monoclonal antibodies raised against phosphorylated (pSer396/pSer404) tau (PHF1, gift of P. Davies, Albert Einstein College of Medicine, New York, NY). After specific signals were developed by Vectastain Elite ABC kit and DAB peroxidase substrate, the sections were lightly counterstained with hematoxylin. The signals were analyzed using a BX50 microscope system (Olympus).
Data analysis. Statistical analyses were performed using one-way ANOVA or two-tailed unpaired Student's t test for all the comparisons in the behavioral and biochemical results. A p value of Ͻ0.05 was considered significant. All the data were described as mean Ϯ SEM.
Results

Generation of Psen1 c.548G>T KI mice
To investigate the pathogenic mechanism underlying the Psen1 c.548GϾT mutation, we generated a KI mouse in which the c.548GϾT mutation was introduced into Psen1 exon 6 by homologous recombination. The targeting vector includes the 5Ј homologous region (2.49 kb), floxed PGK-neo cassette and the 3Ј homologous region (3.15 kb), in which the c.548GϾT mutation was introduced into the last nucleotide of exon 6 (Fig. 1 A, B) . The ES cells carrying the proper homologous recombination events in the 5Ј and 3Ј homologous regions were confirmed by Southern analysis using the 5Ј and 3Ј external probes, respectively (Fig. 1 B; data not shown), and were injected into mouse blastocysts to generate chimeric mice, which were then used to generate heterozygous mice carrying the targeted allele (targeted/ϩ). Southern analysis of tail genomic DNAs of these mice confirmed that homologous recombination and germline transmission occurred correctly, as demonstrated by the presence of two bands representing the wild-type allele (11.0 kb for both 5Ј and 3Ј external probes) and the targeted allele (5.5 kb for the 5Ј external probe, 8.5 kb for the 3Ј external probe) (Fig. 1C) . The floxed PGK-neo selection cassette was removed by crossing the F1 mice transmitted with the targeted allele to Cre-expressing transgenic mice so as to avoid its possible transcriptional interference on Psen1 expression (Fig. 1 B) . Southern analysis of tail genomic DNAs from the resulting mice confirmed the deletion of the floxed PGK-neo selection cassette using the 3Ј external probe (Fig. 1C) . The targeted allele following the removal of the floxed PGK-neo cassette is termed the KI allele (Fig. 1 B, C) . Additional Southern analysis using the neo probe further confirmed the lack of the floxed PGK-neo cassette as well as the absence of random insertion of the targeting vector in the KI mice (data not shown). The correct introduction of the c.548GϾT mutation was also confirmed by sequencing (Fig. 1 D) .
The c.548GϾT KI/KI homozygous mice were born in Mendelian ratio and were fertile, and adult KI/KI mice were grossly normal in appearance compared with littermate controls. Histological analysis of brain morphology shows that KI/KI brains were indistinguishable from littermate controls (Fig.  1 E) . Using stereological methods, we measured cortical volume in Nissl-stained series sagittal sections and found similar cortical volumes between KI/KI and littermate controls even at 20 months of age (Fig. 1 E) . Western analysis of GFAP, which is elevated accompanying astrogliosis Saura et al., 2004) , indicated no increases in the cerebral cortex of KI/KI mice at 12-20 months of age (Fig. 1 F) . These results suggest that Psen1 c.548GϾT
KI/KI mice do not develop age-dependent neurodegeneration. KI/KI mice are brain specific. A, RT-PCR analysis using primers in exons 4 and 10 shows that aberrantly spliced Psen1 mRNAs (⌬ex6 -7, 495 bp) are detected only in brain tissues but not in the liver, lung or skin. B, Real-time qRT-PCR analysis using primers in exons 4 and 5 shows that levels of Psen1 mRNAs are significantly reduced in the neocortex, hippocampus, and cerebellum of c.548GϾT
KI/KI mice, but not in the liver, lung, and skin. C, Cycloheximide treatment reveals the presence of the aberrantly spliced Psen1 mRNAs in the brain. Northern analysis shows that cycloheximide treatment induces the appearance of the aberrantly spliced Psen1 mRNAs (arrowhead, ⌬ex6 -7), which are smaller in size than the full-length Psen1 mRNAs (ϳ2.8 kb), and this occurs only in the brain but not in the liver. *p Ͻ 0.05, **p Ͻ 0.01. NS, Not significant. All data are expressed as mean Ϯ SEM.
Levels of Psen1 mRNAs and proteins are reduced in c.548G>T KI mice Since the c.548GϾT mutation resides on the splice junction of exon 6 and intron 6, which likely disrupts normal splicing of its transcripts, we evaluated Psen1 mRNA expression in c.548GϾT KI mice. Northern analysis revealed that levels of Psen1 mRNAs are significantly reduced in the cerebral cortex of KI/KI mice throughout their life (from postnatal day 1 to 10 months) (Fig. 2 A) . qRT-PCR also confirmed the reduction of Psen1 mRNAs in c.548GϾT KI mice in a KI allele dosedependent manner, with a ϳ40% reduction in KI/KI mice (Fig. 2 B) . Western analysis disclosed ϳ30% reduction in levels of PS1 NTFs and CTFs in total cortical lysates (Fig. 2C) . Given that levels of Psen1 mRNAs correlated with levels of PS1 proteins in Psen1 Ϫ/Ϫ and Psen1 ϩ/Ϫ mice (Shen et al., 1997) , the discrepancy in the reduction of Psen1 mRNAs (ϳ40%) and proteins (ϳ30%) in c.548GϾT
KI/KI mice may reflect a mechanism suggested in a previous report (Lee et al., 1997) , in which mutant PS1 tends to accumulate in transgenic mouse brains. In contrast, the protein levels of other ␥-secretase complex components-NCT, Aph-1, and Pen-2-were similar among the three genotypic groups (Fig. 2C) .
The presence of aberrant Psen1 splice products in c.548G>T KI mice and their degradation by non-sense-mediated decay We next investigated the mechanism underlying reduced levels of Psen1 mRNAs in the brain of KI/KI mice. The location of the G-to-T transversion responsible for the c.548GϾT mutation suggested that splicing of Psen1 transcripts might be disturbed in KI/KI mice (Fig. 1 A) , because proper splicing requires the exon-intron junction to conform to the consensus sequences (Cartegni et al., 2002) . Indeed, RT-PCR using primers in exons 4 and 10 followed by sequencing showed that in addition to normal splice products containing all exons 4 -10, two aberrant splice products lacking either exon 6 or exons 6 and 7 were produced in c.548GϾT KI/KI brains (Fig. 3A) . Since the skipping of exon 6 or both exons 6 and 7 results in frame shift and the use of downstream premature termination codons that are normally out of frame, we then evaluated whether these abnormal transcripts are degraded by NMD mechanisms, which constitute a surveillance system to prevent production of truncated proteins (Cartegni et al., 2002) . We used cycloheximide, a potent inhibitor of protein synthesis and non-sensemediated decay, to determine whether blockade of NMD would restore the levels of aberrant splice products that are normally degraded by NMD. Indeed, cycloheximide treatment enhanced the stability of the aberrantly spliced transcripts and drastically increased levels of the splice product lacking exons 6 and 7 in KI/KI brains (Fig. 3B) . Quantitative RT-PCR analysis also showed that cycloheximide treatment fully rescued the reduction of Psen1 mRNA levels in KI/KI brains (Fig. 3C) . These results reveal that in addition to the glycine-to-valine conversion at the amino acid residue 183 (p.183GϾV), the c.548GϾT mutation KI/KI mice exhibit reduced ␥-secretase activity. A, In vitro ␥-secretase assay using CHAPSO-solubilized cortical fractions and recombinant N102-FmH (substrates of NICD) followed by Western analysis reveals significant reductions of NICD production in KI/KI and KI/ϩ cortices. III-31C is a ␥-secretase inhibitor, which completely abolishes NICD production. SNAP25 is used as internal loading controls of membrane fraction. B, Left, In vitro ␥-secretase assay using CHAPSO-solubilized cortical fractions at 2-3 months of age and recombinant C100-FmH (substrates of A␤ peptides) displays a marked reduction in de novo production of A␤x-40 and A␤x-42 peptides (n Ն 7) in KI/KI and KI/ϩ mice. Right, In vitro ␥-secretase assay using CHAPSO-solubilized cortical fractions from Psen1 cKO mice (n ϭ 3) shows a marked reduction of de novo production of both A␤x-40 and A␤x-42 peptides. C, Sandwich ELISA measurement of endogenous A␤ peptides reveals a significant decrease of A␤40 but not A␤42 in the cerebral cortex of c.548GϾT
KI/KI mice at ϳ12 months of age (n Ն 5). D, Psen1 wild-type (WT) and p.183GϾV cDNAs support comparable levels of ␥-secretase activity as measured by NICD production in Psen-deficient MEFs transfected with either varying amounts of Psen1 wild-type (1ϫ, 2ϫ, 0.5ϫ WT) or equal amounts (1ϫ) of mutant cDNAs (p.183GϾV, ⌬ex6 -7, or p.257DϾA) along with N⌬E cDNAs (encoding substrates of NICD). **p Ͻ 0.01, ***p Ͻ 0.001. NS, Not significant. All data are expressed as mean Ϯ SEM.
disrupts proper splicing of a portion of the Psen1 transcripts, resulting in the generation of aberrantly spliced products harboring premature termination codons, which were rapidly degraded by NMD mechanisms, leading to a consequent ϳ40% decrease in the expression of full-length Psen1 mRNAs in KI/KI brains.
The reduction of Psen1 mRNAs in c.548G>T KI mice is brain specific PS1 is ubiquitously expressed in many tissues , and reduced Psen dosage has been associated with skin disorders in humans and mice (Xia et al., 2001; Tournoy et al., 2004; Kelleher and Shen, 2010; Wang et al., 2010; Pink et al., 2011) . But in FTD patients, the c.548GϾT mutation gives rise to a brainspecific phenotype with no clinical remarks in other tissues (Dermaut et al., 2004) . We therefore examined whether the c.548GϾT mutation affects Psen1 splicing and expression in non-neural tissues. Interestingly, RT-PCR showed no evidence of aberrant splicing in the liver, lung, and skin of KI/KI mice, whereas the aberrantly spliced mRNAs were readily detected in the neocortex, hippocampus, and cerebellum (Fig. 4 A) . As a result, levels of Psen1 mRNAs are unaltered in the liver, lung, and skin, as shown by quantitative RT-PCR (Fig. 4 B) . Additionally, we also examined expression levels of Psen1 mRNAs in splenocytes, which contain broad spectrums of lymphocyte cell lineages, because Notch, a substrate of ␥-secretase, is involved in regulation of lymphocyte cell development (Pui et al., 1999; Radtke et al., 1999) . Northern analysis showed that expression levels of Psen1 mRNAs are not changed in splenocytes in KI/KI mice (data not shown). Moreover, cycloheximide treatment results in an accumulation of aberrantly spliced Psen1 transcripts in the brain but not in the liver of c.548GϾT
KI/KI mice (Fig. 4C) . These results demonstrate that the c.548GϾT mutation causes aberrant splicing and subsequent reduction of Psen1 expression only in the brain but not in non-neural tissues.
Decreases of ␥-secretase activities in the brain of c.548G>T KI mice
To determine the effect of the c.548GϾT mutation on ␥-secretase activity, we performed in vitro ␥-secretase assays using detergent-solubilized cerebral cortical fractions as the sensitive, direct method (Takahashi et al., 2003) . Using CHAPSOsolubilized fractions from the cerebral cortex of c.548GϾT
KI/KI , c.548GϾT KI/ϩ , and wild-type littermate control mice at 2-3 months of age, we found that ␥-secretase activity is reduced in KI/ϩ mice and further decreased in KI/KI mice, as measured by de novo production of Notch intracellular domain (NICD) from recombinant N102-FmH (substrates of NICD) (Fig. 5A) . Production of NICD was abolished by a specific ␥-secretase inhibitor, III-31C (Fig. 5A) .
APP is the other well established physiological substrate of ␥-secretase and ␥-secretase-mediated cleavages give rise to A␤40 and A␤42 peptides (De Strooper et al., 1998) . We then performed the same in vitro ␥-secretase assay using CHAPSOsolubilized cortical fractions of c.548GϾT KI/KI , c.548GϾT KI/ϩ , and wild-type mice, and found that de novo generation of A␤x-40 and A␤x-42 is drastically reduced in KI mice depending on the KI allele dosage (Fig. 5B) . As a control, we also used cortices of Psen1 conditional KO (cKO) mice, and, similar to our prior finding (Yu et al., 2001) , de novo generation of A␤x-40 and A␤x-42 is robustly reduced in Psen1 cKO mice (Fig. 5B) . In addition, we confirmed a decrease of de novo generation of total A␤ by Western blot (data not shown). We further performed sandwich ELISA to measure steady-state levels of endogenous A␤ peptides. Interestingly, measurement of the peptides showed decreased levels of A␤40 but unchanged levels of A␤42 in the cerebral cortex of c.548GϾT
KI/KI mice at 12 months of age (Fig. 5C) . The difference between de novo A␤ production and steady-state A␤ levels is likely due to the effect of A␤ turnover in vivo (Wang et al., 2006) .
Although the reduction of ␥-secretase activities in c.548GϾT KI mice is consistent with decreased Psen1 mRNA levels in these mice, the c.548GϾT mutation also results in a substitution of glycine with valine at amino acid residue 183. To determine whether the p.183GϾV conversion itself alters ␥-secretase activity, we transfected vectors expressing either wild-type at varying amounts (1ϫ, 2ϫ, 0.5ϫ) or various mutant Psen1 cDNAs (1ϫ) and truncated Notch1 (N⌬E) into Psen-deficient MEFs (Herreman et al., Figure 6 . The Psen1 c.548GϾT allele does not cause tau pathology in KI/KI mice. A, Phosphorylation status of tau protein in KI/KI cerebral cortices. Total cortical protein lysates were subject to Western analysis for phosphorylated tau (PHF1 and CP13) and total tau. The signals of phosphorylated tau were divided by those of total tau. B, The representative photos of immunohistochemistry for phospho-tau (PHF1). There is no significant change of tau phosphorylation in the neocortex and hippocampal areas CA1 and CA3. Scale bar, 10 m. NS, Not significant. All data are expressed as mean Ϯ SEM.
2000). One day after the transfection, we collected cell lysates and performed Western analysis. Wild-type and p.183GϾV PS1 displayed similar levels of ␥-secretase activity, as measured by production of NICD, whereas PS1 bearing a p.257DϾA substitution, which abolishes ␥-secretase activity, was unable to produce detectable NICD (Fig. 5D) . The Psen1 mutant cDNA lacking exons 6 and 7 was similarly devoid of ␥-secretase activity (Fig. 5D) . These results suggest that full-length PS1 harboring the p.183GϾV alteration has normal ␥-secretase activity; thus, this change is unlikely to be pathogenic. Collectively, these results suggest that the pathogenic effect of the c.548GϾT mutation is a consequence of the brain-specific reduction in Psen1 mRNA expression.
Absence of tau pathology in the brain of c.548G>T KI mice
In addition to cerebral atrophy, FTD is sometimes associated neuropathologically with tau pathology (Neary et al., 2005) . Neuropathological analysis of the patient carrying the PSEN1 c.548GϾT mutation revealed Pick's body and phosphorylated tau staining, in addition to severe frontotemporal atrophy and clear neuronal loss (Dermaut et al., 2004) . Therefore, we next examined whether levels of tau and phosphorylated status are elevated in the cerebral cortex of KI/KI mice. Western analysis using rabbit polyclonal antibody for total tau showed similar levels of tau in the hippocampus and the neocortex between KI/KI and wild-type littermate mice (Fig.  6A and data not shown). Using monoclonal antibodies PHF1 (specific for phosphorylated Ser396/Ser404) and CP13 (specific for phosphorylated Ser202/Thr205), we found no significant changes phospho-tau in the neocortex and hippocampus of KI/KI mice (Fig. 6A) . Immunohistochemical analysis using PHF1 antibodies further confirmed similar levels of phospho-tau in the neocortex and hippocampal areas CA1 and CA3 regions of KI/KI mice compared with littermate controls at 20 months of age (Fig. 6B) . These results show that the Psen1 c.548GϾT mutation does not cause tau pathology in mice, which may be due to the subtle effect of the mutation and the short lifespan of mice.
Mild spatial memory impairment of c.548G>T KI mice in the Psen2
؊/؊ background We previously reported that loss of presenilin function in the postnatal cerebral cortex impairs learning and memory in a gene dosage-dependent manner (Yu et KI/KI and littermate wild-type control mice at 18 -20 months of age were subjected to training in the hidden platform water maze for 12 d (four trials a day) followed by four trials of training in the visible platform version of the task. The escape latency (A) and swimming speed (B) of KI/KI mice (n ϭ 5) are similar to that of littermate controls (n ϭ 7) during the 12 d training phase of the hidden platform water maze task. C, KI/KI and littermate control mice also displayed similar quadrant occupancy in the post-training probe trial administered 24 h after the final training session. D, The escape latency in the visible platform version of the task is normal in KI/KI mice. E-H, Psen1 c.548GϾT
KI/KI ;Psen2 Ϫ/Ϫ and littermate control mice at 6 -8 months of age were subjected to training in the hidden platform water maze for 12 d (four trials a day) followed by four trials of training in the visible platform version of the task. Saura et al., 2004) . Whereas Psen2 Ϫ/Ϫ mice exhibited normal learning and memory, conditional inactivation of Psen1 and Psen1/2 in postnatal cerebral cortex caused mild and severe memory deficits, respectively. To determine whether the c.548GϾT mutation impairs presenilin function in cognition, we tested hippocampus-dependent spatial learning and memory using the Morris water maze task. Psen1 c.548GϾT
KI/KI and wildtype littermate control mice were given four trials a day for 12 d, and they performed similarly during the 12 d learning phase (Fig.  7 A, B , latency and swim speed) and in the probe trial 24 h after the final training session (Fig. 7C, quadrant occupancy) . Psen1 c.548GϾT
KI/KI mice also did not show any deficit in the visible cue task (Fig. 7D) . We next examined Psen1 c.548GϾT
KI/KI and littermate control mice in the Psen2-null background, because Psen1 cKO mice exhibit more severe learning and memory deficits in the absence of PS2 compensation . During the 12 d training phase, ANOVA did not show a significant genotype effect in escape latency (Fig. 7E ) (F ϭ 0.709; df ϭ 1,17; p ϭ 0.4114), path length (F ϭ 0.032; df ϭ 1,17; p ϭ 0.8601), and swim speed (Fig. 7F ) (F ϭ 3.549; df ϭ 1,17; p ϭ 0.0768), but Psen1 c.548GϾT
KI/KI ;Psen2 Ϫ/Ϫ mice exhibited significantly lower quadrant occupancy during the probe trial administered 24 h after the last training session ( Fig. 7G ; p Ͻ 0.05), suggesting mild spatial memory impairment. The Psen1 c.548GϾT
KI/KI ;Psen2 Ϫ/Ϫ mice performed normally in the visible cue task (Fig. 7H ) . These results suggest that the Psen1 c.548GϾT mutation causes a functional impairment of presenilin activity in cognition, likely due to reduction of Psen1 expression.
Discussion
Presenilin comprises the catalytic component of the aspartate protease complex ␥-secretase, which plays essential roles during embryonic development (Shen et al., 1997; Wong et al., 1997; Donoviel et al., 1999; Li et al., 2000) . The ␥-secretase complex, which also includes nicastrin, Aph-1, and Pen-2 (Yu et al., 2000; Francis et al., 2002; Goutte et al., 2002) , is involved in the intramembrane cleavage of type I transmembrane proteins such as APP and Notch (De Strooper et al., 1998 . Presenilin is broadly expressed in the brain but mediate unique functions in specific cell types Handler et al., 2000; Saura et al., 2004; WinesSamuelson et al., 2005 WinesSamuelson et al., , 2010 Kim and Shen, 2008; Zhang et al., 2009) . Importantly, we previously showed that selective inactivation of PS in the adult cerebral cortex causes progressive memory impairment followed by age-dependent neurodegeneration in the absence of increases of ␤-amyloid peptides Saura et al., 2004; Wines-Samuelson et al., 2010) . Although these studies support the view that loss of PS function contributes to neurodegeneration and dementia, how PSEN mutations affect its function and lead to AD and FTD remains to be determined. In this study, we generated a novel KI mouse model carrying the FTD-associated PSEN1 c.548GϾT mutation to investigate the underlying pathogenic mechanism and to explore the molecular link between the roles of PSEN mutations in AD and FTD. Unexpectedly, we discovered that the c.548GϾT mutation reduces expression of full-length Psen1 mRNAs as a result of aberrant splicing and NMD-mediated degradation of improper splice products (Figs. 2, 3) , and that the corresponding p.183GϾV change in the protein sequence does not affect PS function in ␥-secretase activity (Fig. 5) . Consistent with this reduction in Psen1 expression, c.548GϾT
KI/KI brains exhibit reduced ␥-secretase activity and mild learning and memory deficits (Figs. 5, 7) . Surprisingly, the aberrant splicing and decreased Psen1 expression elicited by the c.548GϾT mutation are brain specific, illuminating a mechanism by which Psen1 mutations can produce brain-specific phenotypes in FTD patients (Fig. 4) . Collectively, our genetic study shows that the FTD-associated PSEN1 c.548GϾT mutation causes a net loss of presenilin activity due to reduced Psen1 mRNA expression (Fig. 8) .
Interestingly, aberrant splicing of PSEN1 transcripts and abnormal PS1 protein expression has previously been reported in cases of sporadic FTD (Evin et al., 2002) . Moreover, PSEN1 mu- 548GϾT mutation causes exon skipping in ϳ40% of Psen1 transcripts, which were degraded by non-sense-mediated decay mechanisms. The remaining ϳ60% Psen1 transcripts were spliced properly into full-length Psen1 c.548GϾT mRNAs, producing PS1 proteins containing the p.183GϾV variant, which exhibit normal ␥-secretase activity. Thus, the net effect of the c.548GϾT mutation is purely a ϳ40% reduction of Psen1 mRNA expression in the brain, which subsequently decreases presenilin function in the regulation of ␥-secretase activity and cognition. The boxes denote Psen1 exons 1-12, and the green areas correspond to coding sequences. The c.548GϾT mutation shown in red resides at the exon 6 and intron 6 boundary. The blue areas in PS1 protein depict transmembrane domains.
tations identified in other FTD pedigrees also reside at exonintron boundaries, possibly leading to splicing defects (Raux et al., 2000; Borroni et al., 2011) . Thus, failure of proper PSEN1 mRNA splicing and consequent reduction of PS1 expression could represent a common mechanism underlying both sporadic and familial FTD. Supporting the plausibility of such a mechanism in FTD pathogenesis, it has been estimated that ϳ15% of all point mutations causing human genetic disease result in an mRNA splicing defect (Krawczak et al., 1992; Liu et al., 2001) .
Another intriguing discovery of our study is the brain specificity of the splicing defect caused by the c.548GϾT mutation, sparing other tissues from detrimental effects associated with reduced PSEN1 expression. Recent studies have shown an association between haploinsufficiency of ␥-secretase component proteins and familial acne inversa Wang et al., 2010; Li et al., 2011; Pink et al., 2011) . However, our molecular analysis of c.548GϾT KI mice showed that levels of Psen1 mRNAs are only reduced in the brain (Fig. 4) . Further analysis revealed that aberrant splicing and subsequent degradation of transcripts from the c.548GϾT KI allele occur only in the brain but not in other tissues. The detailed molecular mechanism by which aberrant splice products are produced in a brainspecific manner remains to be determined. One possible explanation could be the existence of brain-specific alternative splicing factors (Dredge et al., 2001) . A brain-restricted expression of a specific splicing factors might render the splicing machinery less tolerant of the G Ͼ T transversion at the splice donor site, leading to skipping of this exon only in the brain.
While the effect of the c.548GϾT mutation on the overall level of Psen1 mRNAs is modest, its effect on ␥-secretase activity measured by de novo production of NICD or A␤ peptides in KI brains is surprisingly robust (Fig. 5) . For example, the production of A␤40 peptides in c.548GϾT
KI/KI brains is reduced by ϳ70%. These results indicate that ␥-secretase activity is very sensitive to changes in presenilin dosage, suggesting that small reductions of presenilin expression may be sufficient to produce substantial deficits in its essential functions (e.g., at the synapse). However, in vivo steady-state levels of A␤ peptides are less affected (Fig. 5) , suggesting that a compensatory reduction in A␤ turnover may accompany the reduced A␤ production in KI mice. Consistent with our earlier findings (Yu et al., 2001; Saura et al., 2004) , we found that Psen1 c.548GϾT
KI/KI mice in the Psen2-null background exhibit mild deficits in spatial learning and memory (Fig.  7) . Not surprisingly, the spatial memory deficits exhibited by Psen1 c.548GϾT
KI/KI ;Psen2 Ϫ/Ϫ mice was subtler than those of Psen1 cKO mice, in which PS1 is completely inactivated in excitatory neurons of the adult cerebral cortex, whereas Psen conditional double-knock-out mice exhibit more dramatic memory impairment (Yu et al., 2001; Saura et al., 2004) .
It has been long debated whether PSEN mutations cause a toxic gain of function or a loss of essential functions normally performed by presenilin (Shen and Kelleher, 2007) . PSEN mutations associated with familial AD often lead to selective increases of the longer and more amyloidogenic A␤42 peptides, which has been taken as evidence for the toxic gain-of-function mechanism. However, shortly after the identification of the PSEN mutations in familial AD, such mutations were found to reduce its biological function and ␥-secretase activity in invertebrate models and cell culture systems (Levitan et al., 1996; Song et al., 1999; Seidner et al., 2006) . More recently, a clinical PSEN1 mutation conferring a complete loss of PS1 function and ␥-secretase activity has been described (Heilig et al., 2010) . These findings are consistent with our prior work showing that complete inactivation of presenilin function in the adult mouse brain causes dementia and progressive neurodegeneration, two key features common to AD and FTD Wines-Samuelson et al., 2010) . Thus, impairment of essential PS functions in neuronal survival and memory may be a common property of PSEN mutations in both of these neurodegenerative dementias.
Our findings demonstrate that the FTD-associated c.548GϾT mutation decreases Psen1 mRNA expression, leading to a partial loss of presenilin and ␥-secretase function. However, the amino acid substitution derived from the c.548GϾT mutation p.183GϾV does not affect ␥-secretase activity. Thus, the net effect of the c.548GϾT mutation is limited to the reduction of Psen1 mRNA and protein expression, indicating that a pure loss of PSEN expression is pathogenic. This loss of PS expression without altered PS protein activity offers a possible mechanism to account for the development of neurodegeneration and dementia in the absence of A␤ deposition in FTD. It is presently unclear whether other PSEN mutations that have been associated with FTD also affect PS expression, although the localization of some FTD-associated PSEN mutations at splice junctions (e.g., c.1129AϾT, c.338TϾC) raises the possibility that similar mechanisms may be at play (Ikeda et al., 1996; Raux et al., 2000; Binetti et al., 2003; Portet et al., 2003; Rippon et al., 2003; Halliday et al., 2005; Zekanowski et al., 2006; Bernardi et al., 2009; de Bot et al., 2009; Marcon et al., 2009; Gallo et al., 2010; Borroni et al., 2011) . Future studies will be needed to determine the effects on presenilin function and ␥-secretase activity of other FTD-associated PSEN mutations, which include mutations situated at the splice consensus sites [PSEN1: c.1129AϾT (p.377RϾW) and c.338TϾC (p.113LϾP)] and mutations whose localization suggests simple missense substitution (e.g., PSEN1: p.139MϾV, p.146MϾL, p.226LϾF, p.233MϾL, p.260AϾV, p.412VϾI, p.424LϾH, p.424LϾR; PSEN2: p.62RϾH, p.122TϾR, p.231YϾC, p.239MϾV). These studies may help us understand why some of the same PSEN1 mutations are associated with patients who were initially diagnosed clinically as AD or FTD (Ikeda et al., 1996; Portet et al., 2003; Rippon et al., 2003; Halliday et al., 2005; Zekanowski et al., 2006) . Our findings imply that transgenic approaches in cell culture or mice may not provide a complete picture of the impact of PSEN mutations on PS function and ␥-secretase activity; rather, analysis of PSEN mutations in the context of the genomic locus will be important to evaluate potential effects on mRNA splicing and post-transcriptional regulation of PSEN expression. Whether the pure loss of PSEN expression identified in this study constitutes a common pathogenic mechanism by which PSEN mutations cause FTD remains to be determined.
